Intrinsic value of Corcept Therapeutics - CORT

Previous Close

$13.00

  Intrinsic Value

$153.81

stock screener

  Rating & Target

str. buy

+999%

Previous close

$13.00

 
Intrinsic value

$153.81

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of CORT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  254
  393
  588
  853
  1,203
  1,654
  2,220
  2,916
  3,752
  4,739
  5,884
  7,194
  8,671
  10,317
  12,131
  14,112
  16,255
  18,559
  21,019
  23,632
  26,394
  29,302
  32,354
  35,549
  38,886
  42,365
  45,989
  49,759
  53,680
  57,754
Variable operating expenses, $m
  115
  178
  266
  385
  544
  748
  1,004
  1,318
  1,696
  2,142
  2,660
  3,252
  3,919
  4,663
  5,483
  6,378
  7,347
  8,389
  9,501
  10,682
  11,930
  13,244
  14,624
  16,068
  17,576
  19,149
  20,787
  22,491
  24,263
  26,105
Fixed operating expenses, $m
  36
  37
  37
  38
  39
  40
  41
  42
  43
  44
  44
  45
  46
  47
  49
  50
  51
  52
  53
  54
  55
  56
  58
  59
  60
  62
  63
  64
  66
  67
Total operating expenses, $m
  151
  215
  303
  423
  583
  788
  1,045
  1,360
  1,739
  2,186
  2,704
  3,297
  3,965
  4,710
  5,532
  6,428
  7,398
  8,441
  9,554
  10,736
  11,985
  13,300
  14,682
  16,127
  17,636
  19,211
  20,850
  22,555
  24,329
  26,172
Operating income, $m
  104
  179
  285
  429
  620
  867
  1,176
  1,556
  2,013
  2,553
  3,180
  3,897
  4,706
  5,606
  6,599
  7,684
  8,857
  10,119
  11,466
  12,896
  14,408
  16,001
  17,672
  19,422
  21,249
  23,155
  25,139
  27,204
  29,351
  31,582
EBITDA, $m
  104
  179
  285
  429
  621
  867
  1,176
  1,557
  2,014
  2,554
  3,181
  3,898
  4,707
  5,608
  6,602
  7,686
  8,861
  10,122
  11,470
  12,901
  14,414
  16,007
  17,679
  19,429
  21,257
  23,163
  25,148
  27,214
  29,361
  31,594
Interest expense (income), $m
  0
  0
  1
  2
  4
  7
  10
  15
  21
  28
  36
  46
  57
  70
  85
  102
  120
  140
  161
  184
  209
  235
  263
  292
  322
  354
  388
  423
  459
  497
  536
Earnings before tax, $m
  104
  178
  282
  425
  613
  856
  1,161
  1,535
  1,986
  2,517
  3,134
  3,840
  4,635
  5,521
  6,498
  7,564
  8,718
  9,957
  11,281
  12,687
  14,173
  15,738
  17,380
  19,099
  20,895
  22,767
  24,716
  26,745
  28,854
  31,046
Tax expense, $m
  28
  48
  76
  115
  166
  231
  313
  415
  536
  680
  846
  1,037
  1,251
  1,491
  1,754
  2,042
  2,354
  2,689
  3,046
  3,426
  3,827
  4,249
  4,693
  5,157
  5,642
  6,147
  6,673
  7,221
  7,791
  8,382
Net income, $m
  76
  130
  206
  310
  448
  625
  848
  1,121
  1,450
  1,838
  2,288
  2,803
  3,384
  4,030
  4,743
  5,522
  6,364
  7,269
  8,235
  9,262
  10,347
  11,489
  12,688
  13,943
  15,253
  16,620
  18,043
  19,524
  21,063
  22,664

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  258
  398
  596
  864
  1,219
  1,676
  2,250
  2,954
  3,801
  4,801
  5,962
  7,289
  8,786
  10,453
  12,291
  14,297
  16,470
  18,804
  21,296
  23,943
  26,741
  29,688
  32,780
  36,017
  39,398
  42,923
  46,595
  50,415
  54,387
  58,515
Adjusted assets (=assets-cash), $m
  258
  398
  596
  864
  1,219
  1,676
  2,250
  2,954
  3,801
  4,801
  5,962
  7,289
  8,786
  10,453
  12,291
  14,297
  16,470
  18,804
  21,296
  23,943
  26,741
  29,688
  32,780
  36,017
  39,398
  42,923
  46,595
  50,415
  54,387
  58,515
Revenue / Adjusted assets
  0.984
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
  0.987
Average production assets, $m
  1
  1
  1
  2
  2
  3
  4
  6
  8
  9
  12
  14
  17
  21
  24
  28
  33
  37
  42
  47
  53
  59
  65
  71
  78
  85
  92
  100
  107
  116
Working capital, $m
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -7
  -9
  -10
  -12
  -14
  -16
  -19
  -21
  -24
  -26
  -29
  -32
  -36
  -39
  -42
  -46
  -50
  -54
  -58
Total debt, $m
  18
  43
  79
  129
  194
  277
  382
  511
  666
  849
  1,061
  1,304
  1,578
  1,883
  2,220
  2,587
  2,984
  3,412
  3,868
  4,352
  4,864
  5,403
  5,969
  6,562
  7,180
  7,825
  8,497
  9,196
  9,923
  10,679
Total liabilities, $m
  47
  73
  109
  158
  223
  307
  412
  541
  696
  879
  1,091
  1,334
  1,608
  1,913
  2,249
  2,616
  3,014
  3,441
  3,897
  4,382
  4,894
  5,433
  5,999
  6,591
  7,210
  7,855
  8,527
  9,226
  9,953
  10,708
Total equity, $m
  211
  325
  487
  706
  996
  1,369
  1,838
  2,413
  3,105
  3,922
  4,871
  5,955
  7,178
  8,540
  10,042
  11,681
  13,456
  15,363
  17,399
  19,562
  21,848
  24,255
  26,781
  29,426
  32,188
  35,068
  38,068
  41,189
  44,434
  47,807
Total liabilities and equity, $m
  258
  398
  596
  864
  1,219
  1,676
  2,250
  2,954
  3,801
  4,801
  5,962
  7,289
  8,786
  10,453
  12,291
  14,297
  16,470
  18,804
  21,296
  23,944
  26,742
  29,688
  32,780
  36,017
  39,398
  42,923
  46,595
  50,415
  54,387
  58,515
Debt-to-equity ratio
  0.080
  0.130
  0.160
  0.180
  0.190
  0.200
  0.210
  0.210
  0.210
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
Adjusted equity ratio
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  76
  130
  206
  310
  448
  625
  848
  1,121
  1,450
  1,838
  2,288
  2,803
  3,384
  4,030
  4,743
  5,522
  6,364
  7,269
  8,235
  9,262
  10,347
  11,489
  12,688
  13,943
  15,253
  16,620
  18,043
  19,524
  21,063
  22,664
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  2
  2
  2
  3
  3
  4
  4
  5
  5
  6
  6
  7
  8
  8
  9
  10
  11
  12
Funds from operations, $m
  76
  130
  206
  310
  448
  625
  848
  1,121
  1,450
  1,839
  2,289
  2,804
  3,385
  4,033
  4,746
  5,524
  6,367
  7,273
  8,240
  9,266
  10,352
  11,495
  12,694
  13,950
  15,261
  16,628
  18,052
  19,534
  21,074
  22,675
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
Cash from operations, $m
  76
  130
  206
  311
  448
  626
  849
  1,122
  1,451
  1,840
  2,290
  2,806
  3,387
  4,034
  4,748
  5,526
  6,369
  7,275
  8,242
  9,269
  10,355
  11,498
  12,697
  13,953
  15,264
  16,632
  18,056
  19,538
  21,078
  22,679
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -4
  -4
  -5
  -5
  -6
  -6
  -7
  -8
  -8
  -9
  -10
  -11
New CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
Cash from investing activities, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -3
  -3
  -3
  -4
  -4
  -5
  -6
  -6
  -7
  -8
  -9
  -9
  -11
  -11
  -12
  -12
  -14
  -15
  -15
  -17
  -18
  -19
Free cash flow, $m
  76
  130
  206
  310
  448
  625
  847
  1,120
  1,449
  1,837
  2,287
  2,802
  3,382
  4,029
  4,742
  5,520
  6,362
  7,267
  8,233
  9,260
  10,344
  11,487
  12,685
  13,940
  15,250
  16,617
  18,040
  19,521
  21,060
  22,660
Issuance/(repayment) of debt, $m
  18
  26
  36
  49
  65
  84
  105
  129
  155
  183
  212
  243
  274
  305
  336
  367
  397
  427
  456
  484
  512
  539
  566
  592
  619
  645
  672
  699
  727
  755
Issuance/(repurchase) of shares, $m
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  21
  26
  36
  49
  65
  84
  105
  129
  155
  183
  212
  243
  274
  305
  336
  367
  397
  427
  456
  484
  512
  539
  566
  592
  619
  645
  672
  699
  727
  755
Total cash flow (excl. dividends), $m
  97
  155
  242
  359
  512
  708
  952
  1,249
  1,604
  2,020
  2,500
  3,045
  3,656
  4,334
  5,078
  5,887
  6,760
  7,694
  8,690
  9,744
  10,856
  12,026
  13,251
  14,532
  15,869
  17,262
  18,712
  20,220
  21,787
  23,416
Retained Cash Flow (-), $m
  -79
  -115
  -161
  -219
  -290
  -373
  -469
  -575
  -692
  -817
  -948
  -1,084
  -1,223
  -1,362
  -1,502
  -1,639
  -1,775
  -1,907
  -2,036
  -2,163
  -2,286
  -2,407
  -2,526
  -2,645
  -2,762
  -2,880
  -3,000
  -3,121
  -3,245
  -3,373
Prev. year cash balance distribution, $m
  59
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  14
  22
  34
  51
  73
  103
  142
  191
  251
  323
  408
  506
  619
  746
  887
  1,043
  1,214
  1,398
  1,596
  1,808
  2,032
  2,270
  2,520
  2,782
  3,057
  3,344
  3,643
  3,955
  4,279
  4,616
Cash available for distribution, $m
  77
  41
  81
  140
  222
  335
  483
  674
  912
  1,203
  1,551
  1,961
  2,434
  2,972
  3,577
  4,248
  4,985
  5,787
  6,653
  7,581
  8,570
  9,619
  10,725
  11,888
  13,107
  14,382
  15,712
  17,099
  18,542
  20,043
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  74
  37
  70
  115
  172
  243
  327
  421
  524
  631
  737
  837
  925
  998
  1,050
  1,079
  1,085
  1,066
  1,024
  963
  886
  798
  703
  605
  510
  420
  337
  265
  202
  151
Current shareholders' claim on cash, %
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7
  99.7

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

FINANCIAL RATIOS  of  Corcept Therapeutics (CORT)

Valuation Ratios
P/E Ratio 183.2
Price to Sales 18.1
Price to Book 35.7
Price to Tangible Book
Price to Cash Flow 81.4
Price to Free Cash Flow 81.4
Growth Rates
Sales Growth Rate 62%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 36.6%
Interest Coverage 0
Management Effectiveness
Return On Assets 13.2%
Ret/ On Assets - 3 Yr. Avg. -21.3%
Return On Total Capital 15.7%
Ret/ On T. Cap. - 3 Yr. Avg. -23.7%
Return On Equity 26.7%
Return On Equity - 3 Yr. Avg. -130.9%
Asset Turnover 1.3
Profitability Ratios
Gross Margin 97.5%
Gross Margin - 3 Yr. Avg. 97.3%
EBITDA Margin 9.9%
EBITDA Margin - 3 Yr. Avg. -39%
Operating Margin 12.3%
Oper. Margin - 3 Yr. Avg. -31.9%
Pre-Tax Margin 9.9%
Pre-Tax Margin - 3 Yr. Avg. -39%
Net Profit Margin 9.9%
Net Profit Margin - 3 Yr. Avg. -39%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CORT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CORT stock intrinsic value calculation we used $159 million for the last fiscal year's total revenue generated by Corcept Therapeutics. The default revenue input number comes from 2017 income statement of Corcept Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CORT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CORT is calculated based on our internal credit rating of Corcept Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Corcept Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CORT stock the variable cost ratio is equal to 45.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $35 million in the base year in the intrinsic value calculation for CORT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Corcept Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Corcept Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CORT stock is equal to 8.6%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CORT are equal to 0.2%.

Life of production assets of 10 years is the average useful life of capital assets used in Corcept Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CORT is equal to -0.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $191 million for Corcept Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 114 million for Corcept Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Corcept Therapeutics at the current share price and the inputted number of shares is $1.5 billion.

RELATED COMPANIES Price Int.Val. Rating
NVS Novartis ADR 82.27 59.65  sell
ALDR Alder BioPharm 18.00 1.20  str.sell
PFE Pfizer 37.33 24.58  sell
FOLD Amicus Therape 16.00 0.25  str.sell

COMPANY NEWS

▶ Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list   [May-17-18 04:13PM  American City Business Journals]
▶ May Undervalued Stock Opportunities   [May-12-18 10:02AM  Simply Wall St.]
▶ Corcept: 1Q Earnings Snapshot   [May-08-18 06:55PM  Associated Press]
▶ 10 Healthcare Stocks to Stave Off the Market Flu   [Apr-06-18 02:23PM  InvestorPlace]
▶ Corcept misses 4Q profit forecasts   [Feb-22-18 06:31PM  Associated Press]
▶ Why Corcept Therapeutics Stock Gained 27.4% in January   [Feb-13-18 05:12PM  Motley Fool]
▶ These Biotech Stocks Each Dived More Than 20% Is The Sell-Off Overdone?   [Feb-05-18 04:30PM  Investor's Business Daily]
▶ Biotech Roundup: Who's Popping On Drug, Merger, Earnings News?   [Feb-01-18 04:02PM  Investor's Business Daily]
▶ Why Corcept Therapeutics Shares Climbed 10.8% Today   [Dec-21-17 05:20PM  Motley Fool]
▶ This Biotech Stock Launched After Joining The S&P 600 SmallCap   [04:15PM  Investor's Business Daily]
▶ 5 Health Care Stocks Gurus Are Buying   [Dec-07-17 04:28PM  GuruFocus.com]
▶ 3 Highest Growth Stocks in the Market Today   [Dec-04-17 08:07AM  Motley Fool]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.